SNGX
Soligenix, Inc. Common Stock
stockNASDAQ
soligenix, inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous t-cell lymphoma, oral mucositis, pediatric crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.35 | 2026-10-16 | +2.73% | -2.439 |
| 1M | 0.39 | 2026-09-24 | -6.07% | -0.094 |
| 3M | 0.37 | 2026-07-24 | -2.30% | 0.583 |
| 6M | 1.39 | 2026-04-24 | -73.90% | 2.164 |
| 1Y | 1.58 | 2025-10-24 | -77.04% | 2.003 |
| 2Y | 3.72 | 2024-10-24 | -90.25% | — |
| 5Y | 244.56 | 2021-10-25 | -99.85% | 0.580 |
Soligenix, Inc. Common Stock (NASDAQ:SNGX) stock price today is $0.36, and today's volume is 127,880. SNGX is down 0.480% today. The 30 day average volume is 202,611. SNGX market cap is $7.90M with 21.77M shares outstanding.